Last reviewed · How we verify
PPI-amoxicillin-clarithromycin
PPI-amoxicillin-clarithromycin is a Antibiotic combination therapy with acid suppression Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Helicobacter pylori infection eradication.
This is a triple-therapy combination that uses a proton pump inhibitor to reduce stomach acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection.
This is a triple-therapy combination that uses a proton pump inhibitor to reduce stomach acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection. Used for Helicobacter pylori infection eradication.
At a glance
| Generic name | PPI-amoxicillin-clarithromycin |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Antibiotic combination therapy with acid suppression |
| Target | Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The PPI suppresses gastric acid secretion, creating an optimal environment for the two antibiotics to penetrate the gastric mucosa and eliminate H. pylori. Amoxicillin and clarithromycin are bactericidal agents that target bacterial cell wall and protein synthesis respectively. This combination is a standard first-line or second-line regimen for H. pylori eradication.
Approved indications
- Helicobacter pylori infection eradication
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Taste disturbance
- Headache
- Allergic reactions (amoxicillin)
Key clinical trials
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (PHASE3)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Lignin in Treatment of Helicobacter Pylori Infection (PHASE3)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PPI-amoxicillin-clarithromycin CI brief — competitive landscape report
- PPI-amoxicillin-clarithromycin updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about PPI-amoxicillin-clarithromycin
What is PPI-amoxicillin-clarithromycin?
How does PPI-amoxicillin-clarithromycin work?
What is PPI-amoxicillin-clarithromycin used for?
Who makes PPI-amoxicillin-clarithromycin?
What drug class is PPI-amoxicillin-clarithromycin in?
What development phase is PPI-amoxicillin-clarithromycin in?
What are the side effects of PPI-amoxicillin-clarithromycin?
What does PPI-amoxicillin-clarithromycin target?
Related
- Drug class: All Antibiotic combination therapy with acid suppression drugs
- Target: All drugs targeting Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome
- Manufacturer: National Taiwan University Hospital — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Infectious Disease
- Indication: Drugs for Helicobacter pylori infection eradication
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing